Skip to content
Biodatica
Start free

GERCOR - Multidisciplinary Oncology Cooperative Group

Avignon

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

10mo agoTrial registeredSep 22, 2025Source filing (opens the source filing in a new tab)

Momentum

65no change

Momentum 65 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,289 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Apr 16, 2024

    Gastric Cancer · RECRUITING · sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group · First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

    ClinicalTrials.gov · NCT06253611 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    May 5, 2022

    Metastatic Colorectal Cancer · RECRUITING · sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group · Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

    ClinicalTrials.gov · NCT05310643 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    May 21, 2021

    Colorectal Cancer Metastatic, MSI-H Colorectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group · Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

    ClinicalTrials.gov · NCT04730544 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources